Levi & Korsinsky Announces Investigation of Securities Claims Against Azenta, Inc. (AZTA)

Azenta, Inc. reaffirmed 3%-5% organic revenue growth and 300 basis points of margin expansion in February 2026, but disclosed a $149 million goodwill impairment tied to its Multiomics segment in May 2026, alongside a $160.8 million net loss and substantial guidance reduction. The company did not reference the impairment risk during its February reaffirmation, prompting an investigation into potential securities law violations.